Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-Label Dose Escalation Study of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Subjects With Solid Tumors

NCT01138033 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01138033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01138033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-Label Dose Escalation Study of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Subjects With Solid Tumors
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
July 27, 2010
Completion date
December 21, 2015
Enrollment
74 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

cancer